Sharma Amol, Rao Satish
Division of Gastroenterology and Hepatology, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Handb Exp Pharmacol. 2017;239:59-74. doi: 10.1007/164_2016_111.
Chronic constipation is a common, persistent condition affecting many patients worldwide, presenting significant economic burden and resulting in substantial healthcare utilization. In addition to infrequent bowel movements, the definition of constipation includes excessive straining, a sense of incomplete evacuation, failed or lengthy attempts to defecate, use of digital manoeuvres for evacuation of stool, abdominal bloating, and hard consistency of stools. After excluding secondary causes of constipation, chronic idiopathic or primary constipation can be classified as functional defecation disorder, slow-transit constipation (STC), and constipation-predominant irritable bowel syndrome (IBS-C). These classifications are not mutually exclusive and significant overlap exists. Initial therapeutic approach to primary constipation, regardless of aetiology, consists of diet and lifestyle changes such as encouraging adequate fluid and fibre intake, regular exercise, and dietary modification. Laxatives are the mainstay of pharmacologic treatment for potential long-term therapy in patients who do not respond to lifestyle or dietary modification. After a failed empiric trial of laxatives, diagnostic testing is necessary to understand underlying anorectal and/or colonic pathophysiology. No single test provides a comprehensive assessment for primary constipation; therefore, multiple tests are used to provide complementary information to one another. Dyssynergic defecation, a functional defecation disorder, is an acquired behavioural disorder of defecation present in two-thirds of adult patients, where an inability to coordinate the abdominal, recto-anal, and pelvic floor muscles during attempted defecation exists. Biofeedback therapy is the mainstay treatment for dyssynergic defecation aimed at improving coordination of abdominal and anorectal muscles. A large percentage of patients with dyssynergic defecation also exhibit rectal hyposensitivity and may benefit from the addition of sensory retraining. Our understanding of the pathophysiology of STC is evolving. The advent of high-resolution colonic manometry allows for the improved identification of colonic motor patterns and may provide further insight into pathophysiological mechanisms. In a minority of cases of STC, identification of colonic neuropathy suggests a medically refractory condition, warranting consideration of colectomy. The pathophysiology of IBS-C is poorly understood with multiple etiological factors implicated. Pharmacological advances in the treatment of primary constipation have added therapeutic options to the armamentarium of this disorder. Drug development in the secretagogue, serotonergic prokinetic, and ileal bile acid transporter inhibition pathways has yielded current and future medical treatment options for primary chronic constipation.
慢性便秘是一种常见的持续性病症,影响着全球众多患者,带来了巨大的经济负担并导致大量医疗资源的使用。除了排便次数少之外,便秘的定义还包括过度用力、排便不尽感、排便失败或耗时过长、使用手指辅助排便、腹胀以及大便干结。排除便秘的继发性原因后,慢性特发性或原发性便秘可分为功能性排便障碍、慢传输型便秘(STC)以及以便秘为主的肠易激综合征(IBS-C)。这些分类并非相互排斥,存在显著重叠。原发性便秘的初始治疗方法,无论病因如何,都包括饮食和生活方式的改变,如鼓励充足的液体和纤维摄入、定期锻炼以及饮食调整。泻药是对生活方式或饮食调整无反应的患者潜在长期治疗的主要药物治疗手段。在经验性试用泻药失败后,需要进行诊断测试以了解潜在的肛门直肠和/或结肠病理生理学。没有单一的测试能对原发性便秘进行全面评估;因此,多种测试相互补充以提供信息。排便协同失调是一种功能性排便障碍,是三分之二成年患者中存在的一种后天获得性排便行为障碍,即排便时无法协调腹部、直肠肛门和盆底肌肉。生物反馈疗法是排便协同失调的主要治疗方法,旨在改善腹部和肛门直肠肌肉的协调性。很大一部分排便协同失调患者还表现出直肠感觉减退,可能会从增加感觉再训练中获益。我们对STC病理生理学的理解正在不断发展。高分辨率结肠测压法的出现有助于更好地识别结肠运动模式,并可能进一步深入了解病理生理机制。在少数STC病例中,结肠神经病变的识别提示病情药物难治,需要考虑行结肠切除术。IBS-C的病理生理学知之甚少,涉及多种病因。原发性便秘治疗方面的药理学进展为该疾病的治疗手段增添了更多选择。促分泌剂、5-羟色胺能促动力剂和回肠胆汁酸转运体抑制途径的药物研发为原发性慢性便秘带来了当前和未来的治疗选择。